Details of the Drug

General Information of Drug (ID: DMCMOS8)

Drug Name
L-cysteine
Synonyms
52-90-4; Cystein; Half-cystine; (R)-Cysteine; Thioserine; (R)-2-Amino-3-mercaptopropanoic acid; L-(+)-Cysteine; L-Cystein; (2R)-2-amino-3-sulfanylpropanoic acid; beta-Mercaptoalanine; Half cystine; FREE CYSTEINE; Cysteine, L-; L-Cys; L-Alanine, 3-mercapto-; L-Zystein; H-Cys-OH; Cisteinum [Latin]; L-2-Amino-3-mercaptopropionic acid; Cisteina [Spanish]; cisteina; Polycysteine; Cysteinum; Cisteinum; (R)-2-Amino-3-mercaptopropionic acid; L Cysteine; alpha-Amino-beta-thiolpropionic acid; L-2-Amino-3-mercaptopropanoic a
Indication
Disease Entry ICD 11 Status REF
Amyloidosis 5D00 Approved [1]
Bronchiectasis CA24 Approved [2]
Bronchitis CA20 Approved [3]
Paracetamol poisoning N.A. Approved [4]
Non-small-cell lung cancer 2C25.Y Clinical trial [5]
Affected Organisms
Humans and other mammals
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 121.16
Logarithm of the Partition Coefficient (xlogp) -2.5
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C3H7NO2S
IUPAC Name
(2R)-2-amino-3-sulfanylpropanoic acid
Canonical SMILES
C([C@@H](C(=O)O)N)S
InChI
InChI=1S/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1
InChIKey
XUJNEKJLAYXESH-REOHCLBHSA-N
Cross-matching ID
PubChem CID
5862
ChEBI ID
CHEMBL863
CAS Number
52-90-4
UNII
K848JZ4886
DrugBank ID
DB00151
TTD ID
D0L4VI
INTEDE ID
DR2105
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Glutamate-cysteine ligase catalytic (GCLC) DESYL1F GSH1_HUMAN Substrate [6]
Glutamate-cysteine ligase regulatory (GCLM) DEEBDFT GSH0_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Amino acid transporter heavy chain SLC3A1 (SLC3A1) OT56V01A SLC31_HUMAN Regulation of Drug Effects [7]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Gene/Protein Processing [8]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Post-Translational Modifications [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Systemic and cerebral amyloidosis. Ann Med. 1989;21(2):69-72.
2 Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Drug Saf. 2021 Mar;44(3):273-290.
3 Oxidation pathway and exacerbations in COPD: the role of NAC. Expert Rev Respir Med. 2016;10(1):89-97.
4 The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Curr Neuropharmacol. 2021;19(8):1202-1224.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4782).
6 The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase. Adv Enzymol Relat Areas Mol Biol. 1999;73:209-67, xii.
7 Characteristics of transport of selenoamino acids by epithelial amino acid transporters. Chem Biol Interact. 2009 Feb 12;177(3):234-41. doi: 10.1016/j.cbi.2008.09.008. Epub 2008 Sep 19.
8 Differential susceptibility of nonmalignant human breast epithelial cells and breast cancer cells to thiol antioxidant-induced G(1)-delay. Antioxid Redox Signal. 2005 May-Jun;7(5-6):711-8. doi: 10.1089/ars.2005.7.711.